Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism

Abstract

A positive clinical response to infliximab was associated with a higher CRP level before treatment in our population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. We therefore suggest that CRP level may help to identify better candidates for infliximab treatment.

Laboratory markers in IBD: useful, magic, or unnecessary toys?

“…In a Belgian study, in 153 patients treated with infliximab, a baseline CRP .5 mg/l before the start of therapy was associated with a higher response (76%) compared with patients with CRP ,5 mg/l (46%) (p = 0.004). 53 Very similar results have been demonstrated for the humanised anti-TNF molecules CDP-571 and CDP-870, and for the fully human anti-TNF antibodies adalimumab and antiadhesion molecule strategies. [54][55][56] Along the same lines, low or normal baseline CRP values have been associated with a high placebo response and remission rate in clinical trials.…”

Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy

“…The issue has been further discussed by Vermeire and co-workers as CRP is well studied and shown to correlate with disease activity in CD [13]. Increased CRP levels have been suggested to be associated with better response rates in infliximab treatment [14,15]. In the present study we attempted to optimize the utility of CRP by correlating hs-CRP to disease activity and other biomarkers.…”

Prediction of Maintained Mucosal Healing in Patients with Crohn's Disease under Treatment with Infliximab Using Diffusion-Weighted Magnetic Resonance Imaging

“…Aside from imaging, many laboratory data are available regarding predictors of response for short- and long-term clinical benefit during therapy with biological agents [15,16,17]. Survival analysis demonstrated that patients in whom CRP levels normalized early (after 4 weeks of a 10-week period) had better long-term outcomes.…”

“…Survival analysis demonstrated that patients in whom CRP levels normalized early (after 4 weeks of a 10-week period) had better long-term outcomes. The CRP level at the time of endoscopy significantly correlated with the degree of mucosal healing [16,17]. The positive predictive value of 51.8% for continuing remission at 54 weeks means that a clinician could predict a 1-year response in a patient.…”